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in Women with Chlamydia trachomatis Genital
Infection: How Much Do We Know?
Sami L. Gottlieb,1 Stuart M. Berman,1 and Nicola Low2
1Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, and 2Department of Social and Preventive Medicine,
University of Bern, Switzerland
Background. An important question for chlamydia control programs is the extent to which finding and treating
prevalent, asymptomatic Chlamydia trachomatis genital infection reduces reproductive sequelae in infected women.
Methods. We reviewed the literature to critically evaluate evidence on the effect of chlamydia screening on
development of sequelae in infected women.
Results. Two randomized controlled trials of 1-time screening for chlamydial infection—in a Seattle-area health
maintenance organization and a Danish school district—revealed that screening was associated with an ∼50%
reduction in the incidence of pelvic inflammatory disease over the following year. However, both of these trials
had methodological issues that may have affected the magnitude of observed screening benefits and might limit
generalizability to other populations. A large, nonrandomized cohort of chlamydia screening among US Army
recruits, although limited by lack of outpatient data, did not find a benefit of similar magnitude to the randomized
trials. Methodological limitations restrict valid conclusions about individual benefits of screening using data from
historical cohorts and ecological studies. We identified no trials directly evaluating the effect of chlamydia screening
on subclinical tubal inflammation or damage, ectopic pregnancy, or tubal factor infertility and no studies addressing
the effects of 11 round of screening, the optimal frequency of screening, or the benefits of screening for repeat
infections.
Conclusions. Additional studies of the effectiveness of chlamydia screening would be valuable; feasible study
designs may depend on the degree to which screening programs are already established. In addition, better natural
history data on the timing of tubal inflammation and damage after C. trachomatis infection and development of
more accurate, noninvasive tools to assess chlamydial sequelae are essential to informing chlamydia control efforts.
Routine screening for asymptomatic Chlamydia tra-
chomatis genital infection among young, sexually active
women is a fundamental component of chlamydia con-
trol in many countries [1, 2]. Thus, a critical question
for chlamydia control programs is the extent to which
finding and treating prevalent, asymptomatic chlamyd-
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ial infections reduces the incidence of reproductive tract
sequelae in infected women. Many uncertainties remain
about the natural history of untreated C. trachomatis
infection in leading to sequelae, as Haggerty et al discuss
in this supplement [3]. One of the most important
factors affecting the potential effectiveness of chlamydia
control programs is the timing of tubal inflammation
and damage relative to the acquisition of infection. This
timing profoundly impacts the likelihood that infec-
tions can be identified and treated before development
of short-term sequelae, such as symptomatic pelvic in-
flammatory disease (PID), and before development of
tubal damage that may ultimately lead to long-term
sequelae, such as tubal factor infertility and ectopic
pregnancy. There is little doubt that C. trachomatis in-
fection can lead to sequelae [4] and that chlamydial
infection can be effectively treated with available
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antibiotics [5]. What is less clear, however, is the degree to
which treatment given at various times during the natural
course of infection can interrupt progression to sequelae.
The duration of genital C. trachomatis infection in the ab-
sence of treatment has not been completely elucidated [6], but
available long-term studies suggest that a typical untreated chla-
mydial infection can last a year or longer [7, 8]. Thus, asymp-
tomatic C. trachomatis infections may have been present for
many months when detected by screening. By assuming that
women acquire new chlamydial infections at a steady rate be-
tween screenings and that women are screened consistently at
1-year intervals, the mean duration of each chlamydia infection
detected would be 6 months. With longer screening intervals,
as frequently occurs in the United States [9], duration of in-
fection could be greater. If acute PID and/or tubal damage
primarily occur very soon after acquisition of C. trachomatis
infection, screening will only affect that small proportion of
the infected population who have recently acquired infection.
Screening at less frequent intervals would result in even fewer
women receiving benefit. If, however, tissue-damaging patho-
logic processes are mainly initiated later in the course of in-
fection or continue to be elicited by ongoing infection over an
extended period of time, screening would benefit a greater pro-
portion of infected women.
In preparation for the April 2008 Chlamydia Immunology
and Control Expert Advisory Meeting, we reviewed and criti-
cally evaluated evidence for the effectiveness of chlamydia
screening in reducing the incidence of sequelae in screened
women. We assessed this evidence in the context of achieving
better understanding of chlamydial natural history and path-
ogenesis; thus, we focused primarily on the role of screening
in interrupting progression to upper tract inflammation and
sequelae in already infected women. We did not explore the
effect of screening or other control efforts in reducing trans-
mission of C. trachomatis in a population, which could prevent
sequelae by preventing new incident chlamydial infections in
women in the population. This evidence has recently been re-
viewed elsewhere [10]. Our goals were to assess what is known
about screening and treatment to prevent sequelae in already
infected women, to delineate remaining gaps in knowledge that
have implications for chlamydia control programs, and to out-
line the most important research needs to fill those gaps.
METHODS
We conducted a search of the English-language literature from
1960 through March 2008 with use of the Medline comput-
erized database of the US National Library of Medicine. The
Medical Subject Headings and free text terms “chlamydia,”
“Chlamydia trachomatis,” and “chlamydia infections” (ex-
ploded) were combined with the terms “pelvic inflammatory
disease,” “salpingitis,” “endometritis,” “infertility,” and “ec-
topic pregnancy” (exploded) and then limited to humans and
persons 13 years of age. The search excluded articles focused
primarily on “Chlamydophila pneumoniae.” We also searched
reference lists of articles to identify potential additional
references.
We included original, prospective studies of chlamydia
screening interventions in women that had any of the following
primary outcomes: PID, infertility, or ectopic pregnancy. We
also included registry-based retrospective cohort studies and
ecological studies if they discussed one of the primary outcomes
in relation to chlamydia testing. We did not include cross-
sectional and case-control studies, nor did we include studies
with a primary outcome of screening coverage, chlamydia prev-
alence or incidence, or adverse pregnancy outcomes other than
ectopic pregnancy. We also excluded articles that assessed
screening and outcomes after therapeutic abortion or other
surgical instrumentation.
RESULTS
Our initial literature search yielded 875 unique citations. After
review by an author (S.G.) for the aforementioned inclusion
criteria, a total of 11 articles were selected for critical evaluation:
2 randomized controlled trials [11, 12] and 1 nonrandomized
cohort study [13] that evaluated chlamydia screening inter-
ventions and clinical PID outcomes; 4 registry-based retro-
spective cohort studies evaluating chlamydia testing and long-
term outcomes, including ectopic pregnancy [14–17] and
infertility [17]; and 4 ecological studies of rates of chlamydia
infection and either PID [18–20] or ectopic pregnancy out-
comes (Table 1) [18, 21]. We identified no randomized or
nonrandomized trials of the effect of chlamydia screening on
subclinical tubal inflammation, tubal scarring, or the long-term
outcomes of ectopic pregnancy and tubal factor infertility. We
present the results according to study methods.
Randomized controlled trials. A randomized controlled
trial by Scholes et al [12] is the study cited most widely, in-
cluding by the US Preventive Services Task Force [22], as pro-
viding evidence for the individual benefits of screening. In this
study involving 2607 young women at high risk in a Seattle-
area health maintenance organization (HMO) population, a 1-
time proactive approach of inviting women for chlamydia
screening (64% were tested) significantly reduced the risk of
subsequent PID by ∼50% over the next year, compared with
a control group not invited for testing (relative risk, 0.44; 95%
confidence interval, 0.20–0.88). At the time of this review, these
data remain the best available on the benefits of screening to
prevent PID in infected women. However, some aspects of this
trial raise questions as to whether the magnitude of observed
benefits is generalizable and provides realistic expectations of
benefit in real-world settings.
First, only 7% of the 36,547 women who were randomized
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were ultimately enrolled. Women aged 18–34 years who were
registered with the HMO were randomized to screening and
control groups and then sent a survey to determine study el-
igibility based on a risk score (Table 1). The authors reported
more aggressive contacting of survey nonresponders from the
intervention group to expedite testing appointments after eli-
gibility determination. This may have resulted in the observed
1:1.6 ratio instead of the expected 1:2 ratio between the in-
tervention and control groups, introducing the possibility of
selection bias. It is not clear how such a selection bias might
affect estimation of screening benefits, but randomization may
have been compromised.
Second, by applying the rate of PID in the control group to
person-months in the intervention group, we would expect 21
cases of PID, but only 9 cases were observed. Thus, 12 cases
of PID were apparently prevented by treating 44 women, sug-
gesting that at least 27% of the infections identified by screening
would have progressed to diagnosed PID without any inter-
vention. This figure appears substantially higher than findings
from other studies of asymptomatic populations undergoing
screening who were followed up untreated for 12 months [3,
8]. In addition, C. trachomatis has been implicated in ∼30%
of acute PID cases [23]; thus, even if all chlamydia-associated
cases of PID were prevented by screening, a 50% decrease is
larger than what might be expected on the basis of previous
studies.
Østergaard et al [11] conducted a cluster randomized trial
of 17 high schools in a Danish county, in which students in
intervention schools were offered 1-time screening of home-
collected specimens for C. trachomatis and students in control
schools were given referral information about clinic-based test-
ing. Less than half of the students returned eligibility surveys.
Because 93% of participating students in the intervention group
had C. trachomatis testing performed, compared with only 8%
of control students, the effect of screening could be evaluated.
Female students were followed up in 1 year, and incident PID
was assessed by self-report, with confirmation by pharmacy
records. Outcome assessment was unblinded, and almost 50%
of students were lost to follow-up; thus, this study had a sub-
stantial number of limitations. Nonetheless, it had findings
similar to those from the trial by Scholes et al [12]. The 1-time
screening approach in the Danish study was associated with a
halving of PID occurrence over 1 year (4.2% vs 2.1%; Pp
). Testing of 867 female students and detection of 43 in-.045
fections prevented 9 reported cases of PID among the 443
interviewed students at follow-up. Unlike Scholes et al [12],
Østergaard et al [11] also screened boys attending the same
schools, and this may have had an impact on community trans-
mission, preventing some new infections and reinfections that
could have also led to PID.
Cohort studies. An impact of the magnitude found in these
2 randomized controlled trials should be easy to detect. How-
ever, a large cohort study of chlamydia screening in female US
Army recruits by Clark et al [13] did not reproduce these
findings. In this study, a total of 7053 women participating in
a screening program on Sundays at a basic training intake center
were tested and treated for C. trachomatis infection, and 21,021
women who arrived on different days were not. These women
were followed up for hospitalizations over a mean of 1.5 years
with use of US Army coded administrative data. There were
no significant differences between the screened and unscreened
groups in hospitalization rates for chlamydia-related outcomes
(PID, infertility, or ectopic pregnancy). This study was not
randomized and was limited by lack of outpatient data, which
is a large concern because, at the time of the study, most PID
cases were treated in the outpatient setting [24]. However, it
does raise the issue that the positive effects of screening may
be difficult to ascertain and dependent on the population, and
suggests the effect may be weaker than that observed by Scholes
et al [12], at least in some populations.
The 2 randomized controlled trials and the study by Clark
et al [13] used symptomatic, clinically diagnosed PID as the
study outcome. No randomized trials have directly evaluated
the effect of chlamydia screening on ectopic pregnancy and
infertility, conditions that may not be observed for several years,
in part because young women’s use of contraception to prevent
unplanned pregnancy delays their diagnosis. Three historical
cohort studies in Scandinavian countries and a study in Wis-
consin used clinical and population registers to link C. tra-
chomatis testing records with data on long-term complications
[14–17]. These studies, the findings of which are summarized
in Table 1, yield useful information on the risk of long-term
complications in women with at least 1 diagnosed and treated
C. trachomatis infection but provide little insight on the role
of screening in preventing these complications.
Only one of the historical cohort studies, the Swedish study
by Low et al [17], had information about a comparison group
of women who had never been tested for chlamydia. This group
had lower rates of PID and infertility diagnoses than did women
who were tested, including women who only had negative chla-
mydia test results. This highlights the fact that, outside a ran-
domized trial, women who have not been tested are likely to
be different and probably at lower risk of chlamydial infection,
compared with those who have been tested. Another meth-
odological issue affecting interpretation of these studies relates
to undetected infections. The intensity of C. trachomatis testing
and control has been greater in the 3 Scandinavian countries
in which the cohort studies were done than in most other
European countries [2]. Nonetheless, data reported in the Nor-
wegian and Swedish studies show that most women had only
1–2 tests performed over a 10–14-year period [15, 17]; there-
fore, there is a high likelihood of undetected infections at other
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times. Because C. trachomatis is associated with high rates of
repeat infection [25, 26], women with 1 detected chlamydial
infection are particularly likely to have had 1 other unde-
tected, untreated infection. This would tend to reduce the ob-
served impact of testing on subsequent long-term sequelae. All
in all, it is difficult to make an unbiased assessment of the
benefits of screening using these types of observational data.
Ecological studies. Ecological studies have been cited as
showing the effectiveness of screening programs, based on co-
incident decreases in chlamydia and chlamydia-related out-
comes observed in regions that were the earliest to initiate
chlamydia control efforts (Table 1) [18, 19, 21]. During the
1980s and early 1990s, when chlamydia control activities were
being implemented, rates of identified chlamydial infection de-
creased in conjunction with rates of PID [18, 19] and ectopic
pregnancy [18, 21]. However, in some areas, PID rates appeared
to be decreasing before the chlamydia control programs started
[18, 19], and many factors, such as decreases in the number
of gonorrhea infections, increases in safer sex with the human
immunodeficiency virus (HIV) epidemic, and better diagnosis
and treatment of symptomatic C. trachomatis infection, oc-
curred at a similar time. Since the late 1990s in Australia, out-
patient clinical encounter rates for PID have continued to de-
crease among young women, whereas rates of reported
chlamydia cases have increased substantially [20]. Similar find-
ings have been observed in British Columbia [27]. Chlamydia
control programs may well be contributing to ongoing de-
creases in chlamydia-associated sequelae, but ecological studies
cannot be used to determine causality.
DISCUSSION
Summary of existing data. Only a few studies have evaluated
the direct benefits of screening for C. trachomatis genital in-
fection. Two randomized controlled trials of 1-time screening
for chlamydial infection—in a Seattle-area HMO and a Danish
school district—revealed an ∼50% reduction in the incidence
of PID among screened women in the following year. However,
both of these trials had methodological issues that may have
affected the magnitude of observed screening benefits in the
populations evaluated and that might limit the generalizability
of these findings to real-world settings. A large, nonrandomized
cohort of chlamydia screening among US Army recruits did
not find a substantial reduction in the number of hospitali-
zations for PID. Data from historical cohorts have methodo-
logical limitations that restrict the capacity to make valid con-
clusions about the benefits of screening. Ecological studies have
generally supported the effectiveness of chlamydia control pro-
grams in decreasing population-wide sequelae. However, be-
cause of coincident temporal changes in behavior, clinical prac-
tices, and rates of other infections, no firm conclusions can be
drawn about the role of chlamydia screening in reducing com-
plications, and it is impossible to assess benefit on an individual
level.
Gaps in knowledge. At present, it is unknown whether
findings similar to those observed in the randomized controlled
trials reviewed here would be found in other populations pos-
sibly at lower risk, and it is also unclear whether the screening
efforts implemented in these trials apply to screening programs
currently in place. Perhaps most important, major gaps in
knowledge include whether screening and treatment of asymp-
tomatic, prevalent infection can prevent long-term sequelae,
such as infertility and ectopic pregnancy—the outcomes we
most want to prevent. Most of the studies we reviewed evaluated
only 1-time screening, and there is little understanding of the
overall benefits to an individual of 11 round of screening, the
optimal frequency of screening, or the benefits of screening for
recurrent infections [10]. In addition, the relative benefits of
different types of screening approaches to prevent sequelae have
not been evaluated. Finally, development of optimal screening
strategies is limited by gaps in knowledge related to the natural
history of C. trachomatis infection. For example, understanding
the benefits of screening for infertility prevention depends in
part on whether the pathologic processes leading to symptom-
atic PID (the main outcome in available trials) are the same
as those leading to long-term outcomes. The effectiveness of a
screening strategy also depends on the risk and timing of tubal
damage relative to acquisition of infection and the mean du-
ration of infection in the targeted population. Inaccurate mea-
surement of the outcomes of chlamydial infection hampers our
ability to evaluate screening strategies in both research and
nonresearch settings.
Implications. Direct evidence about the effectiveness of
finding and treating prevalent, asymptomatic chlamydial in-
fection in preventing adverse sequelae clearly has major im-
plications for chlamydia control efforts. Sequelae of chlamydial
infection in a population can be prevented either by curing
existing infections before they progress to PID and/or tubal
damage or by preventing new C. trachomatis infections [28].
How a chlamydia control program should be structured, there-
fore, depends on the relative effectiveness of screening in re-
ducing sequelae in infected women, compared with interrupt-
ing transmission and, thereby, reducing incidence in the
population. Chlamydia screening has often been perceived as
providing its main benefit through identification of women
with chlamydial infection early enough to treat them and pre-
vent progression to sequelae in those individuals [22]. This is
the type of benefit that was evaluated in the trial by Scholes et
al [12]. Until recently, cost-effectiveness analyses evaluating
chlamydia screening as a way to prevent PID were structured
around halting disease progression in already infected women
rather than using screening as a tool to decrease transmission
and prevent new infections in a population [29, 30]. A program
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focused primarily on reducing the number of sequelae in in-
fected women makes the most sense if women with asymp-
tomatic, prevalent infections still receive a substantial amount
of benefit from treatment (ie, if tubal inflammation and damage
would continue to be elicited beyond the time that a typical
infection is detected by screening). However, if screening has
little impact on preventing sequelae in infected women, because
tubal damage, if it is to occur, happens relatively soon after the
infection is acquired, control programs must focus primarily
on reducing incidence of new chlamydial infection in the pop-
ulation. A program to reduce incidence of new infection in a
population through interruption of chlamydia transmission
might put greater emphasis, for example, on treatment of sex
partners. Thus, more-precise estimates of the benefits of chla-
mydia screening to an individual infected woman may lead to
consideration of new ways to optimally restructure chlamydia
control programs to reduce adverse outcomes of chlamydial
infection in a population.
Next steps and research needs. Additional studies of the
effectiveness of detecting and treating asymptomatic, prevalent
chlamydial infection in preventing sequelae would be useful.
For countries that do not currently have an active chlamydia
screening program in place as the standard of care, randomized
controlled trials to better delineate the individual benefits of
screening [12] could be done and would be valuable. Before
the National Chlamydia Screening Programme was fully estab-
lished in England, a randomized controlled trial of 1-time chla-
mydia screening among college-aged women was conducted
and recently completed [31]. Published data from the trial were
released too late for inclusion in this review but are available
now [32]. Ideally, screening studies would collect data in a way
that does not focus solely on prevention of PID in screened
individuals, but also includes an assessment of community-
wide benefits. Screening a group of women could reduce trans-
mission in a population and, thus, prevent new infections, with
their own attendant risk of sequelae, in women in the whole
population.
Countries considering implementation of chlamydia screen-
ing programs have the opportunity to use randomization ap-
proaches, such as the stepped wedge design, to systematically
evaluate the effects of screening, as is currently being done in
the Netherlands [33]. In areas where screening for C. trachom-
atis infection is already recommended, assessments of the ben-
efits of screening may be more challenging. However, additional
creative approaches that make comparisons according to
changes in screening intensity and coverage would add insight.
Community randomization to evaluate the benefits of enhanced
chlamydia screening efforts is currently being undertaken in
Australia and provides an opportunity to collect valuable in-
formation (J. Hocking, personal communication). However,
potential methodological problems need to be anticipated, in-
cluding underlying baseline differences in community chla-
mydia prevalence, achieving high screening coverage, testing
and treatment of sex partners, and accurate, unbiased ascer-
tainment of outcomes.
A better understanding of the natural history of C. trachom-
atis infection is also essential to improving and informing chla-
mydia control efforts [3]. Ideally, natural history studies would
help better clarify the incidence and timing of PID and tubal
damage leading to long-term sequelae after untreated chla-
mydial infection. Such assessments would need to be done in
different populations, including asymptomatic women with
prevalent infection who have no indication for testing other
than screening. Because it would be unethical to withhold treat-
ment from a woman with known diagnosed infection and it is
impossible to know when an infection was acquired when de-
tected by screening, evaluations of the natural history of chla-
mydia will be difficult. However, studies that provide insight
on some aspects of natural history may still be possible [34,
35]. Prospective studies that have obtained genital specimens
for other reasons (eg, human papillomavirus natural history
studies or vaccine trials and HIV prevention trials) should be
explored as opportunities for better understanding chlamydia
natural history, provided that study participants have given
consent to test stored specimens and that chlamydia screening
has been offered in accordance with standards of care. Addi-
tional natural history data on repeat infections would also be
useful [3], because these could help assess the importance of
rescreening efforts. Ultimately, we would benefit from more-
specific information about when treatment needs to be pro-
vided to prevent sequelae and whether treatment of long-stand-
ing prevalent infection has a tangible impact on complications.
Better data on natural history would be helpful in modeling,
shaping, and evaluating screening strategies in the context of
a comprehensive chlamydia control program; such data would
inform targeting of screening, the optimal frequency of screen-
ing, and resource allocation for screening women versus man-
aging sex partners.
A critical component of research addressing chlamydia nat-
ural history and the impact of chlamydia screening is our ability
to accurately measure the sequelae of C. trachomatis infection.
We desperately need better, noninvasive tools to measure the
complications of chlamydial infection. Diagnosis of acute PID
is notoriously subjective, insensitive, and nonspecific [23, 36].
Infertility has multiple causes and may not be recognized for
years after a chlamydial infection has caused tubal damage,
because the affected woman may not have tried to become
pregnant. Ectopic pregnancy is a more clear-cut diagnosis than
is PID and infertility and could be more easily used in linking
with administrative inpatient and outpatient data to assess out-
comes. However, ectopic pregnancy is an uncommon outcome
and its timing also depends on efforts or behaviors associated
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with becoming pregnant. Thus, ideally, we need tools not only
to more accurately assess the sequelae observed as end-products
(eg, PID, ectopic pregnancy, and infertility) but also to detect
the intervening pathophysiologic processes leading to or pre-
dictive of those sequelae. More proximal, noninvasive markers
of tubal damage would be extremely valuable for natural history
and screening intervention studies and for candidate vaccine
trials [37]. In addition, having the ability to predict individuals
at increased risk of sequelae or reinfection could lead to tar-
geting strategies that identify those who need, for example,
more frequent screening or more intensive follow-up of sex
partners. Thus, a better understanding of the immunologic,
host, and organism factors underlying pathogenesis and se-
quelae and a search for relevant clinical markers could ulti-
mately help guide targeted screening and control efforts [38,
39].
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